VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+35.87%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$211M
AUM Growth
+$211M
(-13%)
Cap. Flow
-$93.6M
Cap. Flow
% of AUM
-44.31%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| 1 |
Delek Logistics
DKL
|
$1.51M |
| 2 |
Western Midstream Partners
WES
|
$1.18M |
| 3 |
Viper Energy
VNOM
|
$953K |
| 4 |
Marathon Petroleum
MPC
|
$839K |
| 5 |
EPR Properties
EPR
|
$814K |
Top Sells
| 1 |
Barings BDC
BBDC
|
$2.75M |
| 2 |
Prospect Capital
PSEC
|
$2.59M |
| 3 |
WhiteHorse Finance
WHF
|
$2.34M |
| 4 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$2.34M |
| 5 |
Nuveen Credit Strategies Income Fund
JQC
|
$2.27M |
Sector Composition
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNTA
126
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $574K | 0.27% |
17,238
-17,954
| -51% | -$598K |
|
127
Vanda Pharmaceuticals
VNDA
$279M
| $574K | 0.27% |
50,163
+14,995
| +43% | +$172K |
|
128
Exelixis
EXEL
$9.95B
| $568K | 0.27% |
23,905
-9,119
| -28% | -$217K |
|
129
Acadia Pharmaceuticals
ACAD
$4.34B
| $566K | 0.27% |
11,674
-1,602
| -12% | -$77.7K |
|
130
Gilead Sciences
GILD
$140B
| $563K | 0.27% |
7,312
-1,637
| -18% | -$126K |
|
131
United Therapeutics
UTHR
$17.7B
| $561K | 0.27% |
4,637
-1,930
| -29% | -$233K |
|
|
RDUS
132
DELISTED
Radius Health, Inc.
RDUS
| $555K | 0.26% |
40,734
+14,444
| +55% | +$197K |
|
133
Enanta Pharmaceuticals
ENTA
$189M
| $554K | 0.26% |
11,031
+2,200
| +25% | +$110K |
|
134
PTC Therapeutics
PTCT
$4.41B
| $551K | 0.26% |
10,864
-1,333
| -11% | -$67.6K |
|
|
AKCA
135
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $550K | 0.26% |
40,123
+9,637
| +32% | +$132K |
|
136
Ligand Pharmaceuticals
LGND
$3.25B
| $548K | 0.26% |
4,903
-644
| -12% | -$72K |
|
137
Dynavax Technologies
DVAX
$1.19B
| $544K | 0.26% |
+61,331
| New | +$544K |
|
138
Atara Biotherapeutics
ATRA
$88.7M
| $544K | 0.26% |
37,341
+14,070
| +60% | +$205K |
|
139
Insmed
INSM
$30.3B
| $542K | 0.26% |
19,685
-5,670
| -22% | -$156K |
|
140
Ionis Pharmaceuticals
IONS
$9.64B
| $541K | 0.26% |
9,170
-159
| -2% | -$9.38K |
|
141
Sarepta Therapeutics
SRPT
$1.98B
| $540K | 0.26% |
3,369
-1,088
| -24% | -$174K |
|
|
GBT
142
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $539K | 0.26% |
8,542
+885
| +12% | +$55.8K |
|
143
Omeros
OMER
$284M
| $538K | 0.25% |
36,573
-7,344
| -17% | -$108K |
|
|
XLRN
144
DELISTED
Acceleron Pharma Inc.
XLRN
| $535K | 0.25% |
5,613
-6,051
| -52% | -$577K |
|
|
CLVS
145
DELISTED
Clovis Oncology, Inc.
CLVS
| $534K | 0.25% |
79,177
+33,423
| +73% | +$225K |
|
146
Biogen
BIIB
$20.8B
| $528K | 0.25% |
1,972
-45
| -2% | -$12K |
|
147
Golub Capital BDC
GBDC
$3.91B
| $523K | 0.25% |
44,876
-100,096
| -69% | -$1.2M |
|
|
AIMT
148
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $500K | 0.24% |
29,935
+11,135
| +59% | +$186K |
|
|
EPZM
149
DELISTED
Epizyme, Inc
EPZM
| $495K | 0.23% |
30,849
+10,543
| +52% | +$169K |
|
150
Ovid Therapeutics
OVID
$94.6M
| $492K | 0.23% |
+66,717
| New | +$492K |
|